Collaborative publications

Recent publications with ENDIA and TrialNet study groups

Pugliese A, Boulware D, Yu L, Babu S, Steck AK, Becker D, Rodriguez H, DiMeglio L, Evans-Molina C, Harrison LC, et al. The HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotype protects autoantibody-positive relatives from type 1 diabetes throughout the stages of disease progression. Diabetes. 2016 in press.

 

Bingley PJ, Boulware DC, Krischer JP, and Type 1 Diabetes TrialNet Study G. The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes. Diabetologia. 2016;59(3):542-9.

Phillips J, Couper JJ, Penno M, Harrison LC and the ENDIA Study Group (2016) T1D: a disease of developmental origins. Ped Diabetes Aug 15. doi: 10.1111/pedi.12425.

 

Sosenko JM, Skyler JS, Palmer JP, Diabetes Type T, and Diabetes Prevention Trial-Type 1 Study G. The development, validation, and utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS). Current diabetes reports. 2015;15(8):626.

Smith MJ, Packard TA, O'Neill SK, Henry Dunand CJ, Huang M, Fitzgerald-Miller L, Stowell D, Hinman RM, Wilson PC, Gottlieb PA, et al. Loss of anergic B cells in prediabetic and new-onset type 1 diabetic patients. Diabetes. 2015;64(5):1703-12.

 

Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M, Sosenko JM, Krischer JP, Palmer JP, et al. beta cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest. 2015;125(3):1163-73.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Group. The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months. Diabetes Care 2015 38(5):940-2.

Green JB, Bethel A, Armstrong PW, Buse JB and the TECOS Study Group (including Colman PG). Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New Engl J Med, 373:232-242 2015.

Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP, Type 1 Diabetes T, Diabetes Prevention Trial-Type 1 Study Group. A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history. Diabetes Care 2015 38:271-276

Miao D, Steck AK, Zhang L, Guyer KM, Jiang L, Armstrong T, Muller SM, Krischer J, Rewers M, Yu L; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Group. Electrochemiluminescence assays for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1 diabetes risk. Diabetes Technology & Therapeutics 2015 17(2):119-27

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA, Boulware DC, Matheson D, Cuthbertson D, Herold KC, Eisenbarth G, Palmer JP, Type 1 Diabetes T, Diabetes Prevention Trial-Type 1 Study Group. Use of the diabetes prevention trial-type 1 risk score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes. Diabetes Care 2014 37:979-984

Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, Moran A, Raskin P, Rodriguez H, Schatz DA, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Study Group. B-lymphocyte depletion with rituximab and beta-cell function: Two-year results. Diabetes Care 2014 37:453-459

Beam CA, Gitelman SE, Palmer JP, Type 1 Diabetes TrialNet Study Group. Recommendations for the definition of clinical responder in insulin preservation studies. Diabetes 2014 63:3120-3127

Penno MA, Couper JJ, Craig ME, Colman PG, Rawlinson WD, Cotterill AM, Jones TW, Harrison LC; ENDIA Study Group. Environmental determinants of islet autoimmunity (ENDIA): A pregnancy to early life cohort study in children at-risk of type 1 diabetes. BMC Pediatrics 2013 13:124

ORIGIN Trial Investigations (including Colman PG). Does hypoglycaemia increase the risk of cardiovascular events ? A report from the ORIGIN trial. Ever Heart J (2013). 34:3137-44

 

ORIGIN Trial Investigations (including Colman PG) Characteristics associated with maintenance of mean A1c <6.5% in people with dysglycaemia in the ORIGIN Trial. Diabetes Care 2013, 36:2915-22.

Roep BO, Solvason N, Gottlieb PA, Abreu JRF, Harrison LC, Eisenbarth GS, Yu L, Levitan M, Hagopian WA, Buse JB, Von Herrath M, Quan J, King RS, Robinson WH, Utz PJ, Garren H, The BHT Investigators (including Colman PG), Steinman L. Plasma-ecoded proinsulin preserves c-peptide while specifically reducing proinsulin-specific CD8+T cells in type 1 diabetes. Sci Transl Med 5, l9lra82 (2013). Issue: 191

Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G, Type 1 Diabetes TrialNet Study Group, Diabetes Prevention Trial-Type 1 Study Group. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care 2013 36:2615-2620

Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP; T1D TrialNet and Diabetes Prevention Trial–Type 1 Study Group (inc. Harrison LC) (2013). Acceleration of the loss of the first-phase insulin response during the progression to T1D in diabetes prevention trial-type 1 participants. Diabetes 62:4179-83.

Krischer JP, Type 1 Diabetes TrialNet Study Group. The use of intermediate endpoints in the design of type 1 diabetes prevention trials. Diabetologia 2013 56:1919-1924

Diabetes Research in Children Network Study Group, Type 1 Diabetes TrialNet Study Group, Buckingham BA, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA, Bremer AA, Slover R, Cantwell M. The effects of inpatient hybrid closed-loop therapy initiated within 1 week of type 1 diabetes diagnosis. Diabetes Technology & Therapeutics 2013 15:401-408

Buckingham B, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA, Bremer AA, Slover R, Tamborlane WV, Diabetes Research in Children Network Study Group, Type 1 Diabetes TrialNet Study Group. Effectiveness of early intensive therapy on beta-cell preservation in type 1 diabetes. Diabetes Care 2013 36:4030-4035

Yu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL, Type 1 Diabetes TrialNet Study Group. Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care 2012 35:1213-1218

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP, Type 1 Diabetes TrialNet Study Group, Diabetes Prevention Trial-Type 1 Study Group. The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes. Diabetes Care 2012 35:1552-1555

Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM, Type 1 Diabetes TrialNet Study Group. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes Trialnet data. Diabetes 2012 61:2066-2073

Vehic K, Cuthbertson D, Boulware D, Beam CA, Rodriguez H, Legault L, Hyytinen M, Revers M, Schatz DA, Krisler JP and the TEDDY TRIGR, Diabetes Prevention Trial – Type 1 and Type 1 Diabetes TrialNet Natural History Study Groups. Performance of glycated haemoglobin (HbA1c) as an early diagnostic indicator of type 1 diabetes in children and youth. Diabetes Care 35:1821-1825,2012.

The ORIGIN Trial investigators (including Colman PG). N-3 fatty acids and cardiovascular outcomes in patients with dysglycaemia. New Engl J Med 367:309-318, 2012